The purpose of this study was evaluating the early diagnostic value of two specific tubular markers neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) in diabetes nephropathy. Patients and Methods: Cross-sectional study was carried in three groups of patients from 10/2017 to 10/2018 in Military Hospital 103. Group I included 30 healthy peoples with estimated glomerular filtration rate (eGFR) >60 mL/min/1.73 m 2 and urine albumin creatinine ratio (uACR) <30 mg/g. Group II included 30 type 2 diabetic patients having uACR <30 mg/g, eGFR >60 mL/min/1.73 m 2. Group III included 30 type 2 diabetic patients having uACR >30 mg/g, eGFR >60 mL/min/1.73 m 2. Results: Urine KIM-1 and NGAL increased progressively from control group (57.29 ± 25.91 pg/mL; 25.71 ± 13.69 ng/mL) to the group of diabetic patients with uACR <30 mg/g (167.06 ± 44.01 pg/mL; 37.42 ± 10.89 ng/mL) and the group of diabetic patients with uACR ≥30 mg/g) (p < 0.05). There were moderate correlations between KIM-1 (r = 0.48, p < 0.05) and NGAL (r = 0.45, p < 0.05) with uACR. There was a mild correlation between KIM-1 and NGAL (r = 0.29, p < 0.05). KIM-1 and NGAL are the independent tests to detect diabetic nephropathy. The sensivity and specificity of KIM-1 with cutoff value of 174.95 pg/mL were 62.37% and 73.48%, respectively; the sensivity and specificity of NGAL with cutoff value of 35.2 ng/mL were 60.45% and 70.37%, respectively. Conclusion: KIM-1 and NGAL in urine are independent markers for early diagnostic diabetic nephropathy.

Background: The transforming growth factor-beta 1 (TGF-β1) has been demonstrated as one of the main factors in the progression of fibrosis and sclerosis glomerular damages. Glomerulonephritis is one common cause of chronic kidney disease (CKD) with the promotion of inflammatory renal damage containing fibrosis and sclerosis glomerular. Objectives: This study aimed to evaluate the TGF-β1 level in CKD patients and compare it with the healthy control group. Methods: This cross-sectional case-control study was carried out on 212 subjects admitted to the Nghe An Friendship General Hospital in Vietnam from March 2018 to February 2020. The case group included 152 patients diagnosed with CKD caused by glomerulonephritis, and the control group included 60 healthy individuals. The TGF-β1 was determined in serum by ELISA method. Results: The serum TGF-β1 concentration of the healthy control group and CKD group was 13.45 ± 7.17 and 32.35 ± 11.74, respectively. The CKD group had a significantly higher TGF-β1 level than the control group (P < 0.05). The CKD group with the eGRP ≥ 60 mL/min/1.73 m2 group had a higher TGF-β1 level than the eGRP < 60 mL/min/1.73 m2 group, and the TGF-β1 level increased from stage 1 to stage 5 (P < 0.001). The TGF-β1 had a medium correlation to urea, creatinine, and hs-CRP. Conclusions: The concentration of TGF-β1 in the CKD group was higher than the control group so that it increased early from the first stage of the disease.

Background: Chronic kidney disease (CKD) is an increasingly common disease worldwide and has become a global health problem, especially in Vietnam. Cystatin C is a marker for the detection, classification, and prognosis of CKD. Cystatin C is filtered entirely through the glomerular membrane, reabsorbed, and metabolized completely in the renal tubules. In case of damage to the kidneys, glomerular filtration rate declines, and some substances increase in the blood, such as cystatin C. The concentration of cystatin C changes with damage to the renal system. Objectives: This study aimed to estimate the concentration of cystatin C and its variation in the different stages of CKD. Methods: A descriptive, cross-sectional study was conducted on 40 healthy individuals and 137 patients with CKD grade III, IV, and V in 103 Hospital. The concentration of cystatin C was estimated in all subjects. Results: Cystatin C plasma levels were significantly higher in the CKD group (9.17 ± 3.75 mg/L) than in the control group (0.82 ± 0.12 mg/L). Cystatin C plasma levels increased linearly with the serious kidney failure as the stage of CKD. Conclusions: Cystatin C is an effective marker for estimating kidney damage in CKD.

Objectives: We aimed to determine the parameters of acid-base balance in patients with chronic renal failure (CRF) and the relationship between the parameters evaluating acid-base balance and creatinine clearance. Methods: The current cross-sectional study was conducted on 300 patients with CRF (180 males and 120 females). Clinical examination and blood tests by taking an arterial blood sample for blood gas measurement as well as venous blood for biochemical tests to select study participants were performed. Results: Patients with CRF in the metabolic acidosis group accounted for 74%, other types of disorders were less common. The average pH, PCO2, HCO3, tCO2 and BE of the patient group were 7.35 ± 0.09, 34.28 ± 6.92 mmHg, 20.18 ± 6.06 mmol/L, 21.47 ± 6.48 mmHg and-4.72 ± 6.61 mmol/L respectively. These parameters are lower than normal values and decrease by progressing chronic kidney disease (CKD) stage. These parameters correlated moderately with creatinine clearance. Conclusions: In patients with CRF, metabolic acidosis is predominant, and acid-base balance parameters are positively correlated with creatinine clearance.